02 December 2021
Canaural®, a popular otitis externa treatment from Dechra Veterinary Products, has returned to the veterinary market.
The only treatment that uniquely uses fusidic acid, framycetin and nystatin, Canaural has both antibacterial and antifungal properties making it highly active against the most common organisms associated with otitis externa.
Fusidic acid has skin penetrating properties and is highly active against staphylococci and also active against streptococci1. Framycetin is active against Gram negative species, while the combination of the two provides an enhanced antibacterial effect on the most common bacterial cause of canine otitis2.
Canaural also features nystatin that is highly active against Malassezia, Prednisolone helps to provide anti-inflammatory and anti-pruritic action. The sesame oil base helps the medication penetrate throughout the ear canal.
Dechra Brand Manager Claire Morgan said: “The reintroduction of Canaural to the veterinary treatment market means that once again veterinarians have this reliable and effective ear drop treatment available to tackle one of the most common canine complaints.
“Canaural is a tried and tested product and a recent study showed that fusidic acid is highly efficacious against both methicillin sensitive and methicillin resistant strains of Staphylococcus pseudintermedius3. Canaural remains as relevant today as it has ever been.”
Canaural comes in 15 ml and 25 ml bottle sizes and is now available in veterinary wholesalers.
Dechra offers a range of products to support the first line treatment and long-term management of canine otitis including treatments Osurnia and Recicort. For more information on Dechra’s otitis range, visit www.dechra.com.
1 Trial report GB 182 (2001)
2 Nuttall, T.J. et al (2011) Fusidic acid and framycetin show synergistic antimicrobial activity in vitro , Abstracts of the 25th Annual Congress of the ECVD-ESVD, 8–10 September 2011, Brussels, Belgium Veterinary Dermatology, 22, 468
3 Clark et al (2015) Susceptibility in vitro of canine methicillin-resistant and –susceptible staphylococcal isolates to fusidic acid, chlorhexidine and miconazole: opportunities for topical therapy of canine superficial pyoderma. Journal of Antimicrobial Chemotherapy 70 (7), 2048-2052
Canaural® returns to Dechra offering